Lumicell nabs FDA approval for drug-device breast cancer detection system

The Massachusetts-based biotech Lumicell won FDA approval on Thursday for its drug-device combination product used to help detect residual cancer in breast cancer patients, the FDA announced.

The combo of both the optical imaging agent pegulicianine and the company’s Direct Visualization System or another fluorescence imaging…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks